Skip to Content
Print Share

Generic Viberzi Availability

Viberzi is a brand name of eluxadoline, approved by the FDA in the following formulation(s):

VIBERZI (eluxadoline - tablet;oral)

  • Manufacturer: ALLERGAN HOLDINGS
    Approval date: May 27, 2015
    Strength(s): 75MG [RLD], 100MG [RLD]

Has a generic version of Viberzi been approved?

No. There is currently no therapeutically equivalent version of Viberzi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viberzi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds as opioid receptor modulators
    Patent 7,741,356
    Issued: June 22, 2010
    Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 25, 2028
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds as opioid receptor modulators
    Patent 7,786,158
    Issued: August 31, 2010
    Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
    Assignee(s): Janssen Pharmaceutica N.V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 14, 2025
      ✓ 
      Drug substance
  • Compounds as opioid receptor modulators
    Patent 8,344,011
    Issued: January 1, 2013
    Inventor(s): Breslin; Henry J. & Cai; Chaozhong & He; Wei & Kavash; Robert W.
    Assignee(s): Janssen Pharmaceutica, N.V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 14, 2025
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
  • Compounds as opioid receptor modulators
    Patent 8,609,709
    Issued: December 17, 2013
    Assignee(s): Janssen Pharmaceutica, N. V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 14, 2025
      ✓ 
      Drug substance
  • Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
    Patent 8,691,860
    Issued: April 8, 2014
    Assignee(s): Furiex Pharmaceuticals, Inc.
    The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Patent expiration dates:
    • July 7, 2028
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
      ✓ 
      Drug substance
  • Compounds as opioid receptor modulators
    Patent 8,772,325
    Issued: July 8, 2014
    Assignee(s): Janssen Pharmaceutica, N.V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 14, 2025
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
  • Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
    Patent 9,115,091
    Issued: August 25, 2015
    Assignee(s): FURIEX PHARMACEUTICALS, INC.
    The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Patent expiration dates:
    • July 7, 2028
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds as opioid receptor modulators
    Patent 9,205,076
    Issued: December 8, 2015
    Assignee(s): Janssen Pharmaceutica, N.V.
    The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Patent expiration dates:
    • March 14, 2025
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
  • Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
    Patent 9,364,489
    Issued: June 14, 2016
    Assignee(s): Forest Tosara Limited
    The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Patent expiration dates:
    • July 7, 2028
      ✓ 
      Patent use: TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 27, 2020 - NEW CHEMICAL ENTITY
Add to My Med List

More about Viberzi (eluxadoline)

Consumer resources

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide